New daily pill daraxonrasib nearly doubles survival time for advanced pancreatic cancer patients
By
By —
Summary
A new daily pill called daraxonrasib, which targets a gene behind pancreatic cancer, nearly doubled overall survival time for patients with advanced metastatic pancreatic ductal adenocarcinoma (PDAC) compared to standard chemotherapy. In a clinical trial, patients receiving daraxonrasib survived a median of 13.2 months versus 6.7 months for those on standard chemotherapy alone. Researchers and physicians are cautiously optimistic about this breakthrough for one of the deadliest cancers.
Source
bskyNew daily pill daraxonrasib nearly doubles survival time for advanced pancreatic cancer patientsto.pbs.orgKey quotes
· 3 pulledThe overall survival rate for people who got daraxonrasib was 13.2 months, nearly double the 6.7 months people survived on standard chemotherapy alone.
A new drug that targets a gene behind pancreatic cancer has physicians and researchers cautiously optimistic about improved treatment for one of the deadliest cancers.
The hundreds selected for this trial had metastatic pancreatic ductal adenocarcinoma (PDAC), the most common form of pancreatic cancer, that spread to other parts of their bodies and had been previously treated.
You might also wanna read
Daily pill daraxonrasib doubles survival in advanced pancreatic cancer, clinical trial shows
A clinical trial has shown that a daily pill called daraxonrasib can double survival time for patients with advanced pancreatic cancer, one
theguardian.com·1mo ago
Avacta Therapeutics presents platform-validating data for faridoxorubicin in salivary gland cancer at BIO International Conference
Avacta Therapeutics announced platform-validating clinical data for faridoxorubicin (AVA6000), a tumor-activated oncology drug using its pre
avacta.com·6d ago
Promising pancreatic cancer drug may unlock new class of treatments targeting cancer's master switch
The article discusses a promising new drug that targets pancreatic tumors and may have revealed a "master switch" for cancer. The treatment
economist.com·17d ago
Spanish Researchers Develop Breakthrough Therapy Protocol for Pancreatic Cancer Treatment
Spanish researchers have developed a new therapy protocol that could revolutionize pancreatic cancer treatment. Pancreatic cancer is notorio
nypost.com·4mo ago
Mitesh Borad, M.D., an oncologist at Mayo Clinic in Arizona, was part of the research for a new drug proven to give pancreatic cancer patients more time. He speaks on pancreatic cancer, risk factors a
consent.youtube.com
Mitesh Borad, M.D., an oncologist at Mayo Clinic in Arizona, was part of the research for a new drug proven to give pancreatic cancer patients more time. He speaks on pancreatic cancer, risk factors a
consent.youtube.com
Comments
Sign in to join the conversation.
No comments yet. Be the first.